The French pharmaceutical company H.A.C. Pharma boosts its growth strategy in Europe and strengthens its portfolio of drugs with significant therapeutic added value through the acquisition of the European and UK rights to the hematology specialty product TARGRETIN® (bexarotene) from Eisai Co., Limited.

The French pharmaceutical company H.A.C.Pharma continues its growth strategy and strengthens its portfolio of drugs with significant therapeutic added value through the acquisition of the gynecology specialty product TROPHICREME® (estriol) from Sanofi.